Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4053692 | 0.91 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4055078 | 0.85 | SLC6A2 (0.35) | SLC6A2SLC6A3SLC6A4KDM4EALDH1A1 | |
| SCHEMBL4064710 | 0.83 | SLC6A2 (0.40) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4061452 | 0.83 | SLC6A2 (0.35) | SLC6A2SLC6A4KDM4EHTTL3MBTL1 | |
| SCHEMBL4058532 | 0.82 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4KDM4EALDH1A1 | |
| SCHEMBL4053695 | 0.82 | RAB9A (0.40) | SLC6A2SLC6A3SLC6A4ALOX15 | |
| SCHEMBL4055874 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4055055 | 0.81 | SLC6A2 (0.37) | SLC6A2SLC6A3SLC6A4KDM4EHTT | |
| SCHEMBL4062000 | 0.80 | KDM4E (0.38) | SLC6A2SLC6A3SLC6A4KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4941493 | 0.80 | ACHE (0.39) | SLC6A2SLC6A3SLC6A4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A3 3/4885SLC6A4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.